A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis

CNS Drugs

Volumn 28, Issue 2, 2014, Pages 89-94

  Lu, Ellen ^a,b   Wang, Bing Wei ^a,b,c   Alwan, Sura ^a,b   Synnes, Anne ^a,d   Dahlgren, Leanne ^a,d   Sadovnick, A Dessa ^a   Tremlett, Helen ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

^d CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; FINGOLIMOD; FIRATEGRAST; FUMARIC ACID DIMETHYL ESTER; LAQUINIMOD; TERIFLUNOMIDE; CROTONIC ACID DERIVATIVE; FUMARIC ACID DERIVATIVE; IMMUNOLOGIC FACTOR; PROPANEDIOL DERIVATIVE; SPHINGOSINE; TOLUIDINE DERIVATIVE;

BIRTH DEFECT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DRUG SAFETY; EMBRYO DEVELOPMENT; FIRST TRIMESTER PREGNANCY; GROWTH DISORDER; HUMAN; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; ABNORMALITIES, DRUG-INDUCED; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; EPIDEMIOLOGY; FEMALE; ORAL DRUG ADMINISTRATION; PREGNANCY OUTCOME; PRENATAL EXPOSURE;

ABNORMALITIES, DRUG-INDUCED; ADMINISTRATION, ORAL; ANIMALS; CROTONATES; FEMALE; FUMARATES; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; PROPYLENE GLYCOLS; SPHINGOSINE; TOLUIDINES;

EID: 84896876753     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0131-5     Document Type: Review

References (48)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
2. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med. 2011;78(2):161-75.
3. Bayer HealthCare. Betaseron (interferon beta-1b). http://berlex. bayerhealthcare.com/html/products/pi/Betaseron-PI.pdf. Accessed 19 Sep 2012.
4. Serono Inc. Rebif (interferon beta-1a). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/103780s5140lbl.pdf. Accessed 3 Sep 2013.
5. Biogen Idec. Avonex (interferon beta-1a). www.accessdata.fda.gov/ drugsatfda-docs/label/2007/103628s5115lbl.pdf. Accessed 3 Sep 2013.
6. Novartis Pharms. Extavia (interferon beta-1b). http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/125290s0000lbl.pdf. Accessed 3 Sep 2013.
7. Teva Pharmaceuticals. Copaxone (glatiramer acetate). http://www.copaxone. com/pdf/prescribinginformation.pdf. Accessed 19 Sep 2012.
8. EMD Serono I/C. Novantrone (mitoxantrone). http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/019297s030s031lbl.pdf. Accessed 19 Sep 2012.
9. Biogen Idec/Elan Pharmaceuticals Inc. Tysabri (natalizumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/125104s015lbl.pdf. Accessed 19 Sep 2012.
10. Novartis International AG. Gilenya (fingolimod). http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/022527s008lbl.pdf. Accessed 16 Jul 2013.
11. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-15.
12. Sanofi Aventis US. Aubagio (teriflunomide). http://www.accessdata.fda. gov/drugsatfda-docs/label/2012/202992s000lbl.pdf. Accessed 18 Aug 2013.
13. Biogen Idec Inc. Tecfidera (dimethyl fumarate). http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/204063lbl.pdf. Accessed 18 Aug 2013.
14. ClinicalTrials.gov. Laquinimod. http://www.clinicaltrials.gov/ct2/ results?term=laquinimod&Search=Search. Accessed 3 Sep 2013.
15. ClinicalTrials.gov. Firategrast. http://www.clinicaltrials.gov/ct2/ results?term=firategrast&Search=Search. Accessed 3 Sep 2013.
16. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416-26.
17. Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13(3):251-60 (quiz 261).
18. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339(5):285-91.
19. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257(12):2020-3.
20. Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130-5.
21. Ghezzi A, Annovazzi P, Portaccio E, et al. Current recommendations for multiple sclerosis treatment in pregnancy and puerperium. Expert Rev Clin Immunol. 2013;9(7):683-92.
22. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260(5):1202-14.
23. Alwan S, Sadovnick AD. Multiple sclerosis and pregnancy: maternal considerations. Womens Health (Lond Engl). 2012;8(4):399-414.
24. Brown BA, Kantesaria PP, McDevitt LM. Fingolimod: a novel immunosuppressant for multiple sclerosis. Ann Pharmacother. 2007;41(10):1660-8.
25. Cunningham FG, Leveno KJ, Bloom SL, et al. Embryogenesis, and placental development (Chapter 3). 23rd ed. New York: The McGraw-Hill Companies Inc; 2010.
26. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003;121(6):1383-8.
27. Hoxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology. 1998;196(2):223-30.
28. Schilling S, Goelz S, Linker R, et al. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145(1):101-7.
29. Bruck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci. 2011;306(1-2):173-9.
30. Björk A, Jönsson S, Fex T, et al. Quinoline derivatives. United States Patent 6593343. www.google.com.br/patents/US6593343. Accessed 4 Oct 2013.
31. Vukanovic J, Passaniti A, Hirata T, et al. Antiangiogenic effects of quinoline-3-carboxamide linomide. Cancer Res. 1993;53:1833-7.
32. Miller DH, Weber T, Grove R, et al. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012;11(2):131-9.
33. Cunningham FG, Leveno KJ, Bloom SL, et al. Anatomy and physiology: fetal growth and development (Chapter 4). 23rd ed. New York: The McGraw-Hill Companies Inc; 2010.
34. Cunningham FG, Leveno KJ, Bloom SL, et al. Antepartum: teratology and medications that affect the fetus (Chapter 14). 23rd ed. New York: The McGraw-Hill Companies Inc.; 2010.
35. Gelineau-van Waes J, Rainey MA, Maddox JR, et al. Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. Birth Defects Res A Clin Mol Teratol. 2012;94(10):790-803.
36. Wei Q, Runrong G, Xiangdong S, et al. Studies on teratogenicity of dimethyl fumarate. J Hyg Res. 1990;19:28-31.
37. Geissbühler Y, Butzkueven H, Hernández-Diaz S, et al. Multinational Gilenya™ (fingolimod) pregnancy exposure registry: preliminary results [abstract no. P02.134]. Neurology. 2013; 80.
38. Kieseier B, Benamor M, Benzerdjeb H, Stuve O. Pregnancy outcomes from the teriflunomide clinical development programme: retrospective analysis of the teriflunomide clinical trial database [abstract no. P737]. Mult Scler. 2012;18 Suppl 4:328-9.
39. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012;18(9):1278-89.
40. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-303.
41. Gold R, Phillips J, Havrdova E, et al. BG-12 (dimethyl fumarate) and pregnancy: Preclinical and clinical data from the clinical development program [abstract no. P02.129]. Neurology. 2013;80.
42. National Multiple Sclerosis Society. Pregnancy registries for MS medications. http://www.nationalmssociety.org/living-with-multiple-sclerosis/ healthy-living/pregnancy/pregnancy-registry/index.aspx. Accessed 18 Aug 2013.
43. Hellwig K, Haghikia A, Gold R. Parenthood and immunomodulation in patients with multiple sclerosis. J Neurol. 2010;257(4):580-3.
44. Law R, Bozzo P, Koren G, Einarson A. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance? Can Fam Physician. 2010;56(3):239-41.
45. Kweder SL. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Birth Defects Res A Clin Mol Teratol. 2008;82(9):605-9.
46. Limsakun T, Menguy-Vacheron F. Effects of cholestyramine on the elimination of teriflunomide in healthy male volunteers [abstract]. Mult Scler. 2010;16(8):1004.
47. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19(7):835-43.
48. Wiese MD, Rowland A, Polasek TM, et al. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. Expert Opin Drug Metab Toxicol. 2013;9(8):1025-35.